SHEPHERD Therapeutics Presents First Public Data at 2021 ESMO Congress Highlighting Ability of DELVE Computational Approach to Optimize Therapeutic Selection for Cancer Patients

NEXT STORY
Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS
PREV STORY
Sweegen Delights China’s Consumers With Premiumization of Low-Calorie Confectionery Chocolate
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent

- In 179 Relapsed or Refractory IDH1m AML Patients, Primary Endpoint of CR+CRh Rate ...

author_avatar
NASDAQ Market News

Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board

BERKELEY, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference

CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage ...

author_avatar
NASDAQ Market News